Method, oligonucleotide and kit for detecting high-risk hpv
An oligonucleotide and kit technology, applied in the field of detection of high-risk HPV, oligonucleotides and kits, can solve the problems of inability to type, increase the amount of samples and detection reagents, and increase the cost of detection, etc. The effect of ensuring the detection accuracy, reducing the background fluorescence value, and reducing the detection cost
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0046] Embodiment 1: sample DNA extraction
[0047] For the sake of illustration, this embodiment takes a cervical cotton swab sample and the sample nucleic acid extraction reagent used to contain lysate, isopropanol and 1×TE buffer as examples:
[0048] (1) Take out the cervical cotton swab sample, vortex and mix well, pipette 1mL sample into a 1.5mL centrifuge tube, centrifuge at 12000rpm for 1min, carefully discard the supernatant, and keep the precipitate;
[0049] (2) Add 500 μl of lysate to the precipitate in (1), oscillate to mix, and bathe in water or dry bath at 100°C for 10 minutes, wherein the lysate contains 0.2M NaCl, 10mM NaOH, 0.1% SDS, 0.5% NP-40 and 0.5 1×TE buffer of % Tween-20;
[0050] (3) Add 500 μl of isopropanol, vortex and mix, place at room temperature for 2 minutes, centrifuge at 12000 rpm for 5 minutes, discard the supernatant, and place at room temperature for 2 minutes;
[0051] (4) Add 50 μl of 1×TE buffer solution, fully dissolve, let stand at ...
Embodiment 2
[0052] Embodiment 2: fluorescent PCR reaction step
[0053] (1) Prepare high-risk HPV fluorescent PCR reaction solution: 4μl 10×PCR Buffer (100mM Tris-HCl, 500mMKCl); 0.08μl dATP (0.4mM), 0.08μl dTTP (0.4mM), 0.08μl dCTP (0.4mM), 0.08μl dGTP (0.4mM); 0.8μl BSA (10mg / mL); 6.4μl MgCl 2 (25mM); 0.05μl HPV16F (100μM), 0.08μl HPV16F (100μM), 0.08μl Probe1 (100μM); 0.05μl HPV18F (100μM), 0.08μl HPV18F (100μM), 0.08μl Probe2 (100μM); ), 0.08 μl HPV35F (100 μM), 0.08 μl HPV31 / 35R (100 μM), 0.08 μl HPV33F (100 μM), 0.08 μl HPV52F (100 μM), 0.08 μl HPV58F (100 μM), 0.08 μl HPV33 / 52 / 58R (100 μM), 0.06 μl Probe3 (100 μM); 0.08 μl HPV45F (100 μM), 0.06 μl HPV45R (100 μM), 0.08 μl HPV59F (100 μM), 0.06 μl HPV59R (100 μM), 0.06 μl Probe4 (100 μM); 0.08 μl HPV39 / 68M ( 0.08μl HPV39 / 68R (100μM), 0.06μl Probe5 (100μM); ), 0.06 μl Probe6 (100 μM); 0.08 μl HPV26F (100 μM), 0.06 μl HPV51 / 82F (100 μM), 0.08 μl HPV26 / 51 / 82R (100 μM), 0.06 μl Probe7 (100 μM); 0.08 μl HPV73F (100 μM), 0.08 HPV73R (...
Embodiment 3
[0061] Embodiment 3: clinical sample detection
[0062] According to the method in Example 1, the DNA in 140 cases of HPV cervical swab samples was extracted, and then the DNA in the 140 cases of HPV cervical swab samples was subjected to fluorescent PCR amplification according to the method in Example 2. At the same time, for the sake of comparison, the Roche Combas 48014 high-risk HPV (ie HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 and 66) detection kits were used to detect The DNA in the 140 HPV cervical swab samples was detected, and the detection results are shown in Table 4.
[0063] Table 4 Test results
[0064]
[0065]
[0066] The results in Table 4 show that among these 140 clinical samples, the present invention is consistent with the detection results of 134 clinical samples in the Roche kit, but there are also 6 clinical samples, and the present invention can detect the high-risk type The presence of HPV, while the Roche kit cannot detect the pr...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


